- Home
- ANL vs EPIX Comparison
ANL vs EPIX Comparison
Compare ANL & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- EPIX
- Stock Information
- Founded
- ANL 2004
- EPIX 2009
- Country
- ANL Cayman Islands
- EPIX Canada
- Employees
- ANL N/A
- EPIX N/A
- Industry
- ANL
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- EPIX Health Care
- Exchange
- ANL Nasdaq
- EPIX Nasdaq
- Market Cap
- ANL 73.8M
- EPIX 75.9M
- IPO Year
- ANL 2023
- EPIX N/A
- Fundamental
- Price
- ANL $1.47
- EPIX $1.72
- Analyst Decision
- ANL Buy
- EPIX Hold
- Analyst Count
- ANL 2
- EPIX 3
- Target Price
- ANL N/A
- EPIX $2.00
- AVG Volume (30 Days)
- ANL 14.8K
- EPIX 68.7K
- Earning Date
- ANL 08-08-2025
- EPIX 08-04-2025
- Dividend Yield
- ANL N/A
- EPIX N/A
- EPS Growth
- ANL N/A
- EPIX N/A
- EPS
- ANL N/A
- EPIX N/A
- Revenue
- ANL N/A
- EPIX N/A
- Revenue This Year
- ANL N/A
- EPIX N/A
- Revenue Next Year
- ANL N/A
- EPIX N/A
- P/E Ratio
- ANL N/A
- EPIX N/A
- Revenue Growth
- ANL N/A
- EPIX N/A
- 52 Week Low
- ANL $1.10
- EPIX $1.40
- 52 Week High
- ANL $4.10
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- ANL 37.32
- EPIX 55.34
- Support Level
- ANL $1.56
- EPIX $1.60
- Resistance Level
- ANL $1.74
- EPIX $1.73
- Average True Range (ATR)
- ANL 0.15
- EPIX 0.04
- MACD
- ANL -0.01
- EPIX 0.00
- Stochastic Oscillator
- ANL 12.50
- EPIX 76.50
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.